Literature DB >> 9466280

Long-term results of selective renal shielding in patients undergoing total body irradiation in preparation for bone marrow transplantation.

C A Lawton1, E P Cohen, K J Murray, S W Derus, J T Casper, W R Drobyski, M M Horowitz, J E Moulder.   

Abstract

The purpose of this study was to evaluate the effect of partial renal shielding used in conjunction with total body irradiation (TBI) on the incidence of bone marrow transplantation nephropathy (BMT Np) seen as a late sequelae after transplantation. Of 402 patients who have undergone bone marrow transplantation (BMT) at the Medical College of Wisconsin (MCW) 157 were greater than 18 years of age, received 14 Gy TBI and survived at least 100 days post-transplant. The incidence of BMT nephropathy was evaluated in these patients by dose to the kidneys. In the 72 patients who received 14 Gy TBI with no renal shielding, the actuarial risk of developing BMT Np at 2 1/2 years (30 months) post-BMT was 29 +/- 7%. Sixty-eight patients received 14 Gy TBI with partial renal shielding of 15% (renal dose = 11.9 Gy), the actuarial risk of developing BMT Np was 14 +/- 5% at 2 1/2 years. Seventeen patients received 14 Gy TBI with renal shielding of 30% (renal dose = 9.8 Gy); none of this group have developed BMT Np despite a median follow-up of over 2 1/2 years (985 days). The trend of decreasing BMT Np with increasing shielding is statistically significant (P = 0.012). Prognostic factors such as age, type of transplant and good-risk vs poor-risk disease status were evaluated and were similar in each cohort of patients described above. We conclude that given the statistically significant benefit seen here in the reduced incidence of BMT Np by the use of selective renal shielding, this should be seriously considered for all patients who receive TBI, but especially for patients whose renal doses exceed 10 Gy.

Entities:  

Mesh:

Year:  1997        PMID: 9466280     DOI: 10.1038/sj.bmt.1701022

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  19 in total

1.  A case of chronic kidney disease with thrombotic microangiopathy in a hematopoietic stem cell transplant recipient.

Authors:  Kunihiro Maeda; Keisuke Suzuki; Motonori Mizutani; Hitoshi Watanabe; Norihiro Suga; Wataru Kitagawa; Naoto Miura; Kazuhiro Nishikawa; Kazuharu Uchida; Hirokazu Imai
Journal:  Clin Exp Nephrol       Date:  2010-05-15       Impact factor: 2.801

2.  Radiation-induced chronic oxidative renal damage can be reduced by amifostine.

Authors:  Rusen Cosar; Vuslat Yurut-Caloglu; Sevgi Eskiocak; Alaattin Ozen; Semsi Altaner; Kamuran Ibis; Nesrin Turan; Bengu Denizli; Cem Uzal; Mert Saynak; Sule Parlar; Murat Caloglu; Burcu Uregen; Zafer Kocak
Journal:  Med Oncol       Date:  2011-02-24       Impact factor: 3.064

3.  Mitigation of late renal and pulmonary injury after hematopoietic stem cell transplantation.

Authors:  Eric P Cohen; Manpreet Bedi; Amy A Irving; Elizabeth Jacobs; Rade Tomic; John Klein; Colleen A Lawton; John E Moulder
Journal:  Int J Radiat Oncol Biol Phys       Date:  2011-11-19       Impact factor: 7.038

Review 4.  Mitigation of radiation injuries via suppression of the renin-angiotensin system: emphasis on radiation nephropathy.

Authors:  E P Cohen; B L Fish; J E Moulder
Journal:  Curr Drug Targets       Date:  2010-11       Impact factor: 3.465

5.  Renal thrombotic microangiopathy after hematopoietic cell transplant: role of GVHD in pathogenesis.

Authors:  Siribha Changsirikulchai; David Myerson; Katherine A Guthrie; George B McDonald; Charles E Alpers; Sangeeta R Hingorani
Journal:  Clin J Am Soc Nephrol       Date:  2009-01-14       Impact factor: 8.237

6.  Hypertension in long-term survivors of pediatric hematopoietic cell transplantation.

Authors:  Paul A Hoffmeister; Sangeeta R Hingorani; Barry E Storer; K Scott Baker; Jean E Sanders
Journal:  Biol Blood Marrow Transplant       Date:  2009-12-02       Impact factor: 5.742

Review 7.  Chronic kidney disease after hematopoietic cell transplantation: a systematic review.

Authors:  M J Ellis; C R Parikh; J K Inrig; M Kanbay; M Kambay; U D Patel
Journal:  Am J Transplant       Date:  2008-11       Impact factor: 8.086

8.  Incidence and predictors of delayed chronic kidney disease in long-term survivors of hematopoietic cell transplantation.

Authors:  Michael Choi; Can-Lan Sun; Seira Kurian; Andrea Carter; Liton Francisco; Stephen J Forman; Smita Bhatia
Journal:  Cancer       Date:  2008-10-01       Impact factor: 6.860

9.  Captopril to mitigate chronic renal failure after hematopoietic stem cell transplantation: a randomized controlled trial.

Authors:  Eric P Cohen; Amy A Irving; William R Drobyski; John P Klein; Jakob Passweg; Julie-An M Talano; Mark B Juckett; John E Moulder
Journal:  Int J Radiat Oncol Biol Phys       Date:  2007-10-29       Impact factor: 7.038

10.  Long-term renal toxicity in children following fractionated total-body irradiation (TBI) before allogeneic stem cell transplantation (SCT).

Authors:  Johanna Gerstein; Andreas Meyer; Karl-Walter Sykora; Jörg Frühauf; Johann H Karstens; Michael Bremer
Journal:  Strahlenther Onkol       Date:  2009-11-10       Impact factor: 3.621

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.